アブストラクト
| Title | アトピー性皮膚炎・蕁麻疹 |
|---|---|
| Subtitle | 特集 分子標的薬を極める 各論 : アレルギー疾患 |
| Authors | 鎌田昌洋* |
| Authors (kana) | |
| Organization | *帝京大学医学部皮膚科学講座 |
| Journal | 小児内科 |
| Volume | 55 |
| Number | 2 |
| Page | 236-241 |
| Year/Month | 2023 / 2 |
| Article | 報告 |
| Publisher | 東京医学社 |
| Abstract | 「Key Points」(1)アトピー性皮膚炎に対する分子標的薬として, 外用剤ではヤヌスキナーゼ(JAK)阻害薬であるデルゴシチニブ(コレクチム(R))軟膏, ホスホジエステラーゼ(PDE)4阻害薬であるジファミラスト(モイゼルト(R))軟膏がある. (2)内服薬ではJAK1, 2選択的阻害薬であるバリシチニブ(オルミエント(R)), JAK1選択的阻害薬であるウパダシチニブ(リンヴォック(R))とアブロシチニブ(サイバインコ(R))が投与可能である. (3)生物学的製剤では抗IL-4受容体α抗体であるデュピルマブ(デュピクセント(R)), 抗IL-13抗体であるトラロキヌマブ(アドトラーザ(R)), 抗IL-31受容体A抗体であるネモリズマブ(ミチーガ(R))が挙げられる. (4)慢性特発性蕁麻疹は抗ヒスタミン薬内服が治療の中心であるが, 難治な症例では抗IgE抗体であるオマリズマブ(ゾレア(R))が使用される. |
| Practice | 臨床医学：内科系 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) Wollenberg A, Blauvelt A, Guttman-Yassky E, et al:Tralokinumab for moderate-to-severe atopic dermatitis:results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials(ECZTRA 1 and ECZTRA 2). Br J Dermatol 184:437-449, 2021
- 2) Maurer M, Berger W, Gimenez-Arnau A, et al:Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol 150:1498-1506. e2, 2022
- 3) Nakagawa H, Nemoto O, Igarashi A, et al:Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol 144:1575-1583, 2019
- 4) Nakagawa H, Nemoto O, Igarashi A, et al:Delgocitinib ointment in pediatric patients with atopic dermatitis:A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol 85:854-862, 2021
- 5) Saeki H, Baba N, Ito K, et al:Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis:a phase III randomized double-blind, vehicle-controlled trial. Br J Dermatol 186:40-49, 2022
残りの9件を表示する
- 6) Simpson EL, Lacour JP, Spelman L, et al:Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids:results from two randomized monotherapy phase III trials. Br J Dermatol 183:242-255, 2020
- 7) Bieber T, Thyssen JP, Reich K, et al:Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol 35:476-485, 2021
- 8) Guttman-Yassky E, Teixeira HD, Simpson EL, et al:Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis(Measure Up 1 and Measure Up 2):results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 397:2151-2168, 2021
- 9) Simpson EL, Sinclair R, Forman S, et al:Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis(JADE MONO-1):a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 396:255-266, 2020
- 10) Simpson EL, Silverberg JI, Nosbaum A, et al:Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol 22:693-707, 2021
- 11) Simpson EL, Paller AS, Siegfried EC, et al:Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis:A phase 3 randomized clinical trial. JAMA Dermatol 156:44-56, 2020
- 12) Paller AS, Simpson EL, Siegfried EC, et al:Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis:a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400:908-919, 2022
- 13) Kabashima K, Matsumura T, Komazaki H, et al:Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 383:141-150, 2020
- 14) Maurer M, Rosen K, Hsieh HJ, et al:Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368:924-935, 2013
